Talis Biomedical

About:

Talis Biomedical is developing a point-of-care, sample-to-answer platform.

Top Investors: CARB-X

Description:

Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care. The company is developing the Talis One platform, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.

Total Funding Amount:

$8.6M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Menlo Park, California, United States

Founded Date:

2010-01-01

Founders:

Brian Coe, Rustem Ismagilov

Number of Employees:

101-250

Last Funding Date:

2018-05-10

IPO Status:

Public

Industries: